Uses of N-substituted pyridylbenzisocerazolone compounds

N-substituted pyridylbenzisocerazolone compounds, particularly ebselen, address the need for effective coronavirus treatments by inhibiting viral replication through targeting the main protease, providing a broad-spectrum solution for multiple coronavirus diseases with minimal toxicity.

JP7584161B2Active Publication Date: 2024-11-15SHANGHAI TECH UNIV
View PDF 2 Cites 0 Cited by

Patent Information

Application Number
JP2022551023
Authority / Receiving Office
JP · JP
Patent Type
Patents
Current Assignee / Owner
Priority Date
2020-02-24
Filing Date
2021-02-23
Publication Date
2024-11-15
Estimated Expiration
2041-02-23

AI Technical Summary

Technical Problem

There is a lack of effective therapeutic and preventive drugs for diseases caused by coronaviruses, particularly those targeting the main protease of the virus for inhibiting its replication and transcription.

Method used

The use of N-substituted pyridylbenzisocerazolone compounds, specifically ebselen, which targets the main protease active pocket of coronaviruses, is employed to inhibit viral replication and transcription.

Benefits of technology

Ebselen demonstrates strong inhibitory activity against the main protease of coronaviruses, preventing cell degeneration and replication, offering a potential treatment for various coronavirus-induced diseases with low toxic side effects and broad-spectrum efficacy.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 0007584161000018
    Figure 0007584161000018
  • Figure 0007584161000019
    Figure 0007584161000019
  • Figure 0007584161000020
    Figure 0007584161000020
Patent Text Reader

Abstract

The present invention discloses the use of N-substituted pyridylbenzisocerazolone compounds, specifically in the manufacture of medicaments for the treatment and / or prevention of diseases caused by coronaviruses. N-substituted pyridylbenzisocerazolone compounds, such as ebselen, can significantly inhibit the main protease activity of coronaviruses and the intracellular replication ability of SARS-CoV-2, and therefore can be used to treat related diseases caused by coronaviruses.
Need to check novelty before this filing date? Find Prior Art

Description

Detailed Description of the Invention

[0001] This application claims priority to PCT application PCT / CN2020 / 076375, filed on February 24, 2020. This application incorporates the entire text of the above PCT application. [Technical field] The present invention is in the field of biomedical technology, specifically, the use of N-substituted pyridyl benzisocerazolone compounds.

[0002] [Background technology] Coronaviruses are viruses closely related to humans and animals. Coronaviruses HCoV-229E and HCoV-OC43 can cause the common cold (van der Hoek, L., Pyrc, K., Jebbink, M. et al. Identification of a new human coronavirus. Nat Med 2004,10, 368-373). Severe acute respiratory syndrome (SARS) caused by SARS coronavirus caused 8098 infections and 774 deaths worldwide in 2002-2003, with a case fatality rate of 10% (Stadler, K., Masignani, V., Eickmann, M. et al. SARS - beginning to understand a new virus. Nat Rev Microbiol 2003, 1, 209-218). HCo-VNL63, identified in 2004, can also cause a respiratory illness similar to the common cold (van der Hoek, L., Pyrc, K., Jebbink, M. et al. Identification of a new human coronavirus. Nat Med 2004,10, 368-373). In 2012, Middle East Respiratory Syndrome coronavirus (MERS-CoV) emerged, causing 1,728 infections in 27 countries by April 26, 2016, of which 624 died (de Wit, E., van Doremalen, N., Falzarano, D. et al. SARS and MERS: recent insights into emerging coronaviruses. Nat Rev Microbiol 2016,14, 523-534.).The recent epidemic SARS-CoV-2 virus causes COVID-19, whose clinical signs appear as fever, dry cough, and difficulty breathing, and in severe cases can lead to death (Jeannette Guarner, MD, Three Emerging Coronaviruses in Two Decades: The Story of SARS, MERS, and Now COVID-19, American Journal of Clinical Pathology,, aqaa029). Coronaviruses have a major impact on the livestock industry. Porcine epidemic diarrhea virus (PEDV), gastroenteritis virus (TGEV) and porcine delta coronavirus (PDCoV, also known as deltacoronavirus) can cause severe enteritis, diarrhea, vomiting and dehydration in pigs, which can cause significant losses in the pig farming industry (Akimkin V, Beer M, Blome S, et al. New Chimeric Porcine Coronavirus in Swine Feces, Germany, 2012. Emerg Infect Dis. 2016,22(7):1314-1315). Feline infectious peritonitis virus (FIPV) causes a potentially fatal disease in cats. Avian infectious bronchitis virus (IBV) is a widespread poultry disease that infects domestic poultry and has a major economic impact on the poultry industry.

[0003] In phylogenetic classification, coronaviruses belong to the Orthocoronavirinae subfamily of the Coronaviridae family of the Nidovirales order. The genome sequence of the SARS-CoV-2 coronavirus has already been published, and its sequence has about 90% sequence similarity with the nucleotides of SARS-CoV, and its protein sequence has about 80% sequence similarity with SARS-CoV. The coronavirus genome is a single-stranded positive-stranded RNA about 28 kb in length, and mainly encodes structural proteins required for viral packaging and nonstructural proteins related to replication and transcription. The development of medicines and vaccines used to treat coronavirus-related diseases mainly targets the above two types of proteins. Two-thirds of the genes in the viral genome mainly encode nonstructural proteins. The virus encodes two polymerase proteins, pp1a and pp1ab, involved in the viral replication process. pp1a and pp1ab are cleaved into 16 nonstructural proteins nsp1-16 by two virus-encoded proteases, namely papain and main protease, and only when these functional subunits are cleaved into independent protein units by the virus-encoded proteases can the virus complete normal transcription and replication functions and further assemble into a replication-transcription complex to complete viral replication and transcription. Here, papain has three enzyme cleavage sites, and main protease has 11 enzyme cleavage sites in pp1a and pp1ab.Therefore, it has been found that the main protease plays an important regulatory role in the process of viral transcription and replication, and has become the focus of research (Ziebuhr, J.; Snijder, EJ; Gorbalenya, AE Virus-encoded proteinases and proteolytic processing in the Nidovirales. J Gen Virol 2000, 81, 853-79.;Ziebuhr, J. Molecular biology of severe acute respiratory syndrome coronavirus. Curr Opin Microbiol 2004, 7, 412-9.). Due to the importance of the main protease in the amplification and replication of coronaviruses, it is particularly important to search for inhibitors with high specificity and high safety against the catalytic site of the main protease in the development of medicines.

[0004] Ebselen belongs to N-substituted pyridylbenzisoselenium compounds, an organic selenium compound, which has a special function similar to glutathione peroxidase, and can be used as a glutathione peroxidase regulator or mimetic compound, and has excellent antioxidant function. Ebselen is a multifunctional compound that protects important intracellular components from oxidative damage, and it has been found that ebselen can inhibit many enzymes involved in various biological processes, including zinc finger proteins, lipoxygenase, nitric oxide synthase, NADPH oxidase, H+-K+-ATPase, horseradish peroxidase, glutamate dehydrogenase and lactate dehydrogenase (Azad, GK & Tomar, R.SEbselen, a promising antioxidant drug: mechanisms of actionand targets of biological pathways. Mol Biol Rep 2014,41,4865). The molecular formula of ebselen is as follows:

[0005] [ka]

[0006] Ebselen can affect various biological reaction processes in cells, which can act as a scavenger of reactive oxygen and free radicals, exert antioxidant stress function, inhibit cell death, maintain genome stability, as well as affect the immune system, regulate the host immune system, and exhibit anti-inflammatory effects in response to various stimuli (Azad, GK & Tomar, R.S.Ebselen, a promising antioxidant drug: mechanisms of actionand targets of biological pathways. Mol Biol Rep 2014,41,4865).

[0007] Ebselen has excellent anti-inflammatory activity in various inflammation models and does not have the gastrointestinal irritation effect of nonsteroidal anti-inflammatory drugs. In clinical practice, it can be used to treat Meniere's disease and endolymphatic edema, rheumatoid arthritis, osteoarthritis, etc. (Azad, GK & Tomar, R.S.Ebselen, a promising antioxidant drug: mechanisms of actionand targets of biological pathways. Mol Biol Rep 2014,41,4865.;Jonathan Kil, Edward Lobarinas, Christopher Spankovich,et.al. Safety and efficacy of ebselen for the prevention of noise-induced hearing loss: a randomised, double-blind, placebo-controlled, phase 2 trial. The Lancet 2017,390, 969-979.;J. Kier. Treatment of Meniere's Disease; Chinese Patent:CN109475518A, 2019-03-15.). Large oral doses of epselen can cause acute toxicity, with lethal oral doses in rats of >4600 mg / kg and in mice of >2150 mg / kg.In a 2019 patent for the treatment of Meniere's disease, Sound Pharmaceuticals Inc. conducted a Phase II clinical trial of epselen for the treatment of Meniere's disease, and the results showed that epselen showed good safety and tolerability, no obvious toxic side effects were observed, and a small number of patients showed mild headache symptoms, which recovered quickly after discontinuing administration (Jeannette Guarner, MD, Three Emerging Coronaviruses in Two Decades: The Story of SARS, MERS, and Now COVID-19, American Journal of Clinical Pathology, , aqaa029;Akimkin V, Beer M, Blome S, et al. New Chimeric Porcine Coronavirus in Swine Feces, Germany, 2012. Emerg Infect Dis. 2016,22(7):1314-1315.). Clinical trials confirmed that epselen has a high safety profile.

[0008] The prior art (CN1615883A) describes that epselen inhibits HBV virus and treats HBV virus-related diseases, but the patent also discloses that epselen mainly plays an immunoregulatory role, unrelated to the role of main protease, unrelated to viral replication or viral protein synthesis, and epselen is used in combination with other medicines. Up to now, it has not been found that epselen can be used to treat related diseases caused by coronavirus.

[0009] [Summary of the invention] The technical problem to be solved by the present invention is to provide the use of N-substituted pyridylbenzisocerazolone compounds, specifically in the manufacture of medicines for treating coronavirus diseases, in order to solve the shortcomings of the prior art that do not have medicines with effective therapeutic and / or preventive effects on diseases caused by coronaviruses.

[0010] The present invention mainly solves the above technical problems through the following technical solutions: In a first aspect of the present invention, there is provided a use of an N-substituted pyridyl benzisocerazolone compound in the manufacture of a medicament for treating and / or preventing a disease caused by coronavirus, the general formula I of the N-substituted pyridyl benzisocerazolone compound being represented by the following formula:

[0011] [ka]

[0012] In the formula, R1 is selected from hydrogen, halogen, C1-C4 linear or branched alkyl or alkoxy, and the substitution position of R1 is the 3-, 4-, 5- or 6-position; R2 is selected from hydrogen, halogen, C1-C4 linear or branched alkyl or alkoxy, and the substitution position of R2 is any carbon atom on the 2-position pyridine ring; X represents a nitrogen atom, the substitution position being the 2-, 3- or 4-position.

[0013] The N-substituted pyridylbenzisocerazolone compound is preferably a compound represented by the following general formula (Ia):

[0014] [ka]

[0015] where R1 and R2 are as defined above. A compound represented by general formula (Ib):

[0016] [ka]

[0017] R1 and R2 are as defined above, and include compounds represented by general formula (Ic):

[0018] [ka]

[0019] where R1 and R2 are as defined above. The N-substituted pyridylbenzisocerazolone compound is more preferably ebselen represented by the following formula:

[0020] [ka]

[0021] Preferably, the disease is a mammalian or avian disease. Preferably, said mammals include humans, pigs and cats. The coronavirus according to the present invention is defined as known in the art and belongs to the Orthocoronavirinae subfamily of the Coronaviridae family of the Nidovirales order in phylogenetic classification. Coronaviruses are RNA viruses with an envelope and a single positive strand, and are widely present in nature.

[0022] The object of the present invention is to provide a potential method for the treatment of diseases caused by coronavirus infection. The coronavirus according to the present invention preferably belongs to the subfamily Orthocoronavirinae; more preferably belongs to Alphacoronavirus, Betacoronavirus, Gammacoronavirus or Deltacoronavirus.

[0023] In a preferred embodiment of the present invention, the N-substituted pyridylbenzisocerazolone compound such as epselene can be used not only for the treatment of diseases caused by SARS-CoV-2 (Beta coronavirus genus), but also for the treatment of serious infectious diseases caused by SARS-CoV (Beta coronavirus genus) and MERS-CoV, etc., and can be used as a common cold medicine for the treatment of diseases caused by coronaviruses such as HCoV-HKU1 (Human coronavirus HKU1; Beta coronavirus genus), HCoV-NL63 (Human coronavirus NL63; Alpha coronavirus genus), HCoV-OC43 (Human coronavirus OC43) and HCoV-229E (Human coronavirus 22E; Alpha coronavirus genus), and can be used as a veterinary medicine for the treatment of diseases caused by porcine transmissible gastroenteritis virus (TGEV; Alpha coronavirus genus), porcine epidemic diarrhea virus (PEDV; Alpha coronavirus genus), porcine delta coronavirus (PEDV; Alpha coronavirus genus), porcine pulmonary circulation virus (PPV ... It can treat animal diseases such as infectious avian bronchitis virus (IBV; Gamma coronavirus), feline infectious peritonitis virus (FIPV; Alpha coronavirus), and avian infectious bronchitis virus (IBV; Delta coronavirus).

[0024] Thus, the coronavirus of the present invention is preferably selected from SARS-CoV-2, SARS-CoV, MERS-CoV, HCoV-HKU1, HCoV-NL63, HCoV-OC43, HCoV-229E, TGEV, PEDV, PDCoV, FIPV or IBV.

[0025] Before any medicine can be used in clinical practice, it must be prepared into a form suitable for medical and preventive purposes, which is called a pharmaceutical dosage form, or drug for short. By preparing medicines in various dosage forms, not only can patients use and receive them more easily, and the dosage of the medicine be more accurate, but the stability of the medicine can be improved, and sometimes toxic side effects can be reduced, and the storage, transportation and transport of the medicine can be made easier. There are dozens of pharmaceutical dosage forms, and there are 20 to 30 types of commonly used dosage forms such as oral dosage forms and injection dosage forms.

[0026] In the present invention, the dosage form of the pharmaceutical is preferably an oral dosage form. In a second aspect of the present invention, there is provided a method for treating a disease caused by coronavirus using an N-substituted pyridyl benzisocerazolone compound or a pharmaceutical composition containing the same, wherein the general formula I of the N-substituted pyridyl benzisocerazolone compound is represented by the following formula:

[0027] [ka]

[0028] In the formula, R1 is selected from hydrogen, halogen, C1-C4 linear or branched alkyl or alkoxy, and the substitution position of R1 is the 3-, 4-, 5- or 6-position; R2 is selected from hydrogen, halogen, C1-C4 linear or branched alkyl or alkoxy, and the substitution position of R2 is any carbon atom on the 2-position pyridine ring; X represents a nitrogen atom, the substitution position being the 2-, 3- or 4-position.

[0029] The N-substituted pyridylbenzisocerazolone compound is preferably a compound represented by the following general formula (Ia):

[0030] [ka]

[0031] where R1 and R2 are as defined above. A compound represented by general formula (Ib):

[0032] [ka]

[0033] R1 and R2 are as defined above, and include compounds represented by general formula (Ic):

[0034] [ka]

[0035] where R1 and R2 are as defined above. The N-substituted pyridylbenzisocerazolone compound is more preferably ebselen represented by the following formula:

[0036] [ka]

[0037] Here, the dosage form of the pharmaceutical composition is preferably an oral dosage form. In a third aspect of the present invention, there is provided a method for treating a disease caused by coronavirus by administering an N-substituted pyridyl benzisocerazolone compound or a pharmaceutical composition containing the same to an animal suffering from a disease caused by coronavirus, wherein the general formula I of the N-substituted pyridyl benzisocerazolone compound is represented by the following formula:

[0038] [ka]

[0039] In the formula, R1 is selected from hydrogen, halogen, C1-C4 linear or branched alkyl or alkoxy, and the substitution position of R1 is the 3-, 4-, 5- or 6-position; R2 is selected from hydrogen, halogen, C1-C4 linear or branched alkyl or alkoxy, and the substitution position of R2 is any carbon atom on the 2-position pyridine ring; X represents a nitrogen atom, the substitution position being the 2-, 3- or 4-position.

[0040] The N-substituted pyridylbenzisocerazolone compound is preferably a compound represented by the following general formula (Ia):

[0041] [ka]

[0042] where R1 and R2 are as defined above. A compound represented by general formula (Ib):

[0043] [ka]

[0044] R1 and R2 are as defined above, and include compounds represented by general formula (Ic):

[0045] [ka]

[0046] where R1 and R2 are as defined above. The N-substituted pyridylbenzisocerazolone compound is more preferably ebselen represented by the following formula:

[0047] [ka]

[0048] The animal is preferably an animal capable of suffering from a disease caused by a coronavirus, such as a mammal or bird. In the present invention, the mammal preferably includes humans, pigs and cats.

[0049] The specific limitations of the coronavirus, the N-substituted pyridyl benzisocerazolone compounds, and the diseases described in the second and third aspects of the present invention are the same as those of the coronavirus, the N-substituted pyridyl benzisocerazolone compounds, and the diseases described in the first aspect.

[0050] The present invention has discovered through in vitro enzyme activity experiments and in vitro cell virus experiments that ebselen can be used to treat related diseases caused by coronavirus. The positive advances of the present invention are: The present invention has found through in vitro enzyme activity experiments and in vitro cell virus experiments that N-substituted pyridylbenzisocerazolone compounds such as ebselen can be used to treat coronavirus-related diseases. At present, there is no specific medicine for human coronavirus on the market, and ebselen treatment can make up for the shortcomings of existing technology, with low toxic side effects and easy oral administration. [Brief description of the drawings]

[0051] [Figure 1] This shows that epselen has potent inhibitory activity against the main protease of the new coronavirus (SARS-CoV-2). [Diagram 2] Molecular docking shows that epselen is an inhibitor that targets the main protease active pocket of the new coronavirus. [Diagram 3] This shows that epselen can prevent cytopathic changes caused by infection with the new coronavirus (a: addition of epselen, b: new coronavirus-infected cells, c: MOCK control, addition of 0.1% DMSO). [Figure 4] Antiviral tests at the cellular level are shown. [Diagram 5] A structural overlay of the main proteases of different coronaviruses is shown, showing that their substrate / inhibitor (green) binding pockets are highly conservative (structures of 12 coronaviruses were compared, including SARS-CoV-2, SARS-CoV, MERS-CoV, HCoV-HKU1, BtCoV-HKU4, MHV-A59, PEDV, FIPV, TGEV, HCoV-NL63, HCoV-229E and IBV). DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0052] Example 1 In vitro enzyme activity experiments showed that Epselen's IC 50 We found that the α-aminobutyric acid value was 0.48 μM, which significantly inhibited the main protease activity of the new coronavirus (SARS-CoV-2) (Figure 1). As shown by molecular docking, epselen is an inhibitor that targets the main protease active pocket of the new coronavirus (Figure 2).

[0053] In vitro cell virus experiments revealed that epselen can prevent cell degeneration caused by novel coronavirus infection (Figure 3), and epselen can significantly inhibit the intracellular SARS-CoV-2 replication ability (Figure 4). At the same time, clinical trials confirmed that epselen has a high level of safety and can be used to treat diseases caused by coronaviruses.

[0054] For detailed experimental methods of the above in vitro enzyme activity experiments and in vitro cell virus experiments, please refer to Wang, M. et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Research, doi:10.1038 / s41422-020-0282-0 (2020).

[0055] The substrate binding pocket of the main protease of coronaviruses is very conservative (Figure 5), so inhibitors targeting this binding pocket (such as epselen) have a broad-spectrum anti-coronavirus effect. Therefore, epselen of the present invention can be used not only to treat diseases caused by SARS-CoV-2, but also to treat major infectious diseases caused by other coronaviruses such as SARS-CoV and MERS-CoV, and can be used as a common cold medicine to treat diseases caused by coronaviruses such as HCoV-HKU1, HCoV-NL63, HCoV-OC43 and HCoV-229E, and can be used as a veterinary medicine to treat animal diseases such as porcine transmissible gastroenteritis virus (TGEV), porcine epidemic diarrhea virus (PEDV), porcine delta coronavirus (PDCoV), feline infectious peritonitis virus (FIPV), and avian infectious bronchitis virus (IBV).

[0056] Although the specific embodiments of the present invention have been described above, those skilled in the art will recognize that these are merely illustrative examples and may make various changes and modifications to these embodiments without departing from the principles and substance of the present invention. Therefore, the scope of protection of the present invention is limited by the appended claims.

Claims

1. 1. Use of an N-substituted pyridyl benzisocerazolone compound in the manufacture of a medicament for the treatment and / or prevention of a disease caused by a coronavirus, comprising: The N-substituted pyridyl benzisocerazolone compound is represented by the following formula: [Formula 1] Wherein the coronavirus is selected from SARS-CoV-2, SARS-CoV, MERS-CoV, HCoV-HKU1, HCoV-OC43, PDCoV or FIPV.

2. The disease is a mammalian or avian disease, and / or the dosage form of the medicament is an oral dosage form; And / or the use according to claim 1, wherein the medicine is a cold medicine or a veterinary medicine.

3. The use described in claim 2, wherein the mammals include humans, pigs and cats.

Citation Information

Patent Citations

  • Ischemic myocardial damage resistant usage of benzoisoselenothiazolidone compound

    CN1572295A

  • Combined modalities for nucleosides and / or nadph oxidase (NOX) inhibitors as myeloid-specific antiviral agents

    WO2019133712A1